Stay updated on TrkA Inhibitor VMD-928 Clinical Trial

Sign up to get notified when there's something new on the TrkA Inhibitor VMD-928 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TrkA Inhibitor VMD-928 Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Added a new revision entry 'Revision: v3.4.2' to the study record history and removed the 'Notice...' about government funding lapse along with the earlier 'Revision: v3.4.1' entry.
    Difference
    0.6%
    Check dated 2026-02-11T02:40:04.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice about government funding and operating status appears, directing users to cc.nih.gov and opm.gov. The record history version was updated from v3.4.0 to v3.4.1.
    Difference
    0.6%
    Check dated 2026-02-03T23:53:30.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The history page now includes a glossary toggle, visual indicators for additions and deletions, and explicit revision notes to clarify how changes are presented.
    Difference
    0.8%
    Check dated 2026-01-28T00:01:28.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    A new history entry (Revision: v3.3.4) was added and Revision: v3.3.3 was removed from the version history.
    Difference
    0.1%
    Check dated 2026-01-13T19:16:32.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    A new Revision: v3.3.3 entry has been added to the Record History. The HHS Vulnerability Disclosure link and Revision: v3.3.2 entry were removed.
    Difference
    0.2%
    Check dated 2025-12-23T01:35:07.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    The study title was updated from 'Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma' to 'VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma'. The record also updated/added several sections including Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Study Status, and Study Identification.
    Difference
    0.9%
    Check dated 2025-12-15T22:23:57.000Z thumbnail image

Stay in the know with updates to TrkA Inhibitor VMD-928 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TrkA Inhibitor VMD-928 Clinical Trial page.